Pierres M, Germain R N, Dorf M E, Benacerraf B
J Exp Med. 1978 Mar 1;147(3):656-66. doi: 10.1084/jem.147.3.656.
The in vivo effects of intravenous administration of alloantisera directed to I-J subregion coded determinants were investigated. In confirmation and extension of our previous results, anti-I-Jk [B10.A(3R) anti-B10.A(5R)] and anti-I-Js ([B10.A(3R) X B10.S(9R)]F1 anti-B10.HTT) antisera, when administered in 1 to 10 microliter amounts at the time of immunization, led to twofold increases in the IgM and IgG plaque-forming cells (PFC) responses to suboptimal doses of sheep erythrocytes in A/J (I-Jk) and SJL (I-Js) mice, respectively. To assess whether this immunopotentiation was due to a decrease in specific suppression, experiments were carried out using the polypeptide antigens random linear terpolymer of L-glutamic acid60, L-alanine30, and L-tyrosine10 (GAT) and random linear copolymer of L-glutamic acid50-L-tyrosine50 (GT), since administration of GAT to the nonresponder strain SJL, or GT to the nonresponder strain CBA fails to induce a primary PFC response and stimulates specific suppressor T cells able to prevent PFC responses to subsequent challenge with the immunogens GAT-methylated bovine serum albumin (MBSA) or GT-MBSA, respectively. The current study demonstrates that CBA (I-Jk) mice given 100 microgram GT in Maalox-pertussis adjuvant on day 0, and 10 microliter anti-I-Jk antiserum i.v. on days 0, 1, and 2, develop a significant primary specific PFC response on day 7. A similar responsiveness to 10 microgram GAT is found in SJL mice treated with 10 microliter anti-I-Js antiserum for 3 days. This same active anti-I-Js antiserum does not permit CBA mice to respond to GT, demonstrating the specificity of the anti-I-J effect. These data suggest that anti-I-J antiserum treatment at the time of antigen administration reduces suppressor responses to GAT or GT, permitting primary PFC responses. To directly demonstrate such an effect on suppressor activity, SJL or CBA mice treated, respectively, with GAT or GT to induce suppressor cells active on GAT-MBSA or GT-MBSA responses after adoptive transfer to normal syngeneic recipients were also given anti-I-J antisera (10 microliter/day) for 3 days, at which time their spleen cells were tested for suppressive activity upon transfer. Cells from such treated mice failed to show detectable suppressive activity upon transfer to syngeneic recipients challenged with GAT-MBSA or GT-MBSA, confirming the hypothesis of an in vivo effect of anti-I-J antiserum on suppressor activity.
研究了静脉注射针对I-J亚区编码决定簇的同种抗血清的体内效应。为证实并扩展我们之前的研究结果,抗I-Jk[B10.A(3R)抗B10.A(5R)]和抗I-Js([B10.A(3R)×B10.S(9R)]F1抗B10.HTT)抗血清,在免疫时以1至10微升的量给药,分别使A/J(I-Jk)和SJL(I-Js)小鼠对次优剂量绵羊红细胞的IgM和IgG空斑形成细胞(PFC)反应增加两倍。为评估这种免疫增强是否是由于特异性抑制的降低,使用多肽抗原L-谷氨酸60、L-丙氨酸30和L-酪氨酸10的无规线性三元共聚物(GAT)以及L-谷氨酸50-L-酪氨酸50的无规线性共聚物(GT)进行实验,因为给无反应性品系SJL注射GAT,或给无反应性品系CBA注射GT,均不能诱导初次PFC反应,反而刺激了能够分别阻止对免疫原GAT-甲基化牛血清白蛋白(MBSA)或GT-MBSA后续攻击产生PFC反应的特异性抑制性T细胞。当前研究表明,在第0天给予100微克GT并佐以氢氧化铝-百日咳疫苗的CBA(I-Jk)小鼠,以及在第0、1和2天静脉注射10微升抗I-Jk抗血清后,在第7天产生了显著的初次特异性PFC反应。在用10微升抗I-Js抗血清处理3天的SJL小鼠中,发现对10微克GAT有类似的反应性。同样的活性抗I-Js抗血清不能使CBA小鼠对GT产生反应,证明了抗I-J效应的特异性。这些数据表明,在抗原给药时用抗I-J抗血清处理可降低对GAT或GT的抑制反应,从而允许初次PFC反应。为直接证明对抗抑制活性的这种作用,分别用GAT或GT处理以诱导对GAT-MBSA或GT-MBSA反应有活性的抑制细胞,然后将其过继转移至正常同基因受体的SJL或CBA小鼠,也给予抗I-J抗血清(10微升/天),持续3天,此时检测其脾细胞在转移后的抑制活性。来自此类处理小鼠的细胞在转移至用GAT-MBSA或GT-MBSA攻击的同基因受体后,未显示出可检测到的抑制活性,证实了抗I-J抗血清对抑制活性有体内效应的假说。